Intracranial solitary fibrous tumors (SFTs) represent rare mesenchymal neoplasms known for their aggressive recurrence and potential for distant metastasis. Managing WHO grade 3 SFT remains challenging due to the lack of standardized systemic therapies for multi-organ disease. Pazopanib for Solitary Fibrous Tumor management has recently emerged as a promising strategy, particularly for patients with extracranial spread. This case study highlights how a combination of tyrosine kinase inhibition and stereotactic radiotherapy achieved long-term control in a 56-year-old patient.

Clinical Response to Pazopanib for Solitary Fibrous Tumor

The patient initially presented with a cerebellopontine angle tumor that progressed from WHO grade 2 to grade 3 over several years. Despite repeated Gamma Knife radiosurgery (GKRS) and subtotal resection, the disease developed multiple visceral and bone metastases. Consequently, clinicians initiated pazopanib at a flexible daily dose of 200-400 mg. This treatment yielded marked responses in the lung, liver, and pancreatic lesions. Furthermore, it effectively slowed the progression of bone metastases, thereby reducing the frequency of required radiotherapy sessions. However, the drug demonstrated site-dependent efficacy, as intracranial lesions continued to progress despite systemic control.

Integrating Radiotherapy with Systemic Treatment

While pazopanib successfully addressed extracranial disease, the patient required continued local intervention for intracranial progression. Specifically, two additional GKRS sessions were necessary to manage the CNS burden. This highlights a critical limitation of certain antiangiogenic therapies in crossing the blood-brain barrier effectively. Therefore, clinicians must maintain a multi-modal approach, combining systemic agents with localized stereotactic body radiotherapy. Notably, such integration allowed this patient to survive 26 months after starting pazopanib and 8 years from the initial diagnosis.

Practical Lessons and Surveillance

Managing rare tumors requires flexible dosing to ensure long-term treatment sustainability. For instance, maintaining pazopanib at 200-400 mg helped mitigate adverse events while preserving therapeutic efficacy. Additionally, long-term surveillance is vital because SFT metastases often develop many years after achieving initial local control. Clinicians should remain vigilant for visceral spread even when the primary intracranial site appears stable.

Frequently Asked Questions

How effective is Pazopanib for Solitary Fibrous Tumor metastases?

Pazopanib shows high efficacy in controlling visceral metastases, such as those in the liver and lungs. However, its impact on intracranial or CNS lesions is often limited, requiring concurrent local therapies like radiotherapy.

What are the common side effects of Pazopanib in SFT patients?

Patients frequently experience diarrhea, fatigue, and hypertension. Flexible dosing and supportive care are often necessary to manage these toxicities during long-term treatment.

Why is multi-modal therapy necessary for grade 3 SFT?

Grade 3 SFT is highly aggressive and often resists single-modality treatment. Combining surgery, radiotherapy, and systemic agents like pazopanib addresses both local recurrence and distant spread effectively.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Totani M et al. Long-term control of grade 3 intracranial solitary fibrous tumor achieved with pazopanib and stereotactic radiotherapy: illustrative case. J Neurosurg Case Lessons. 2026 Apr 06. doi: undefined. PMID: 41941836.


2. Martin-Broto J et al. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):456-466.


3. Wang C et al. A clinical investigation of extracranial metastases in 17 cases of intracranial solitary fibrous tumors. World J Surg Oncol. 2025;23(1):112.